RxDoctor Payments Data

Gargi Patel, MD

Psychiatry · New Brunswick, NJNPI 1417355959

Payments from drug & device makers

$1,767in general payments, 2019–2025

Across 74 payments — averaging $23.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$472
  • Regeneron Healthcare Solutions, Inc.$467
  • CSL Behring$288
  • Amgen$172
  • Sanofi-aventis U.S. LLC$141
  • Optinose US, Inc.$118
  • plus $110 from 4 others

What the payments were for

  • Food & beverage$1,55688%
  • Education$21112%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,767 in reported general payments places this provider in the 80th percentile of 1,119 psychiatry providers in New Jersey.

See all psychiatry providers in New Jersey

Medicare billing

Part B allowed, 2024
$39,752
Medicare patients
120
Services billed
391

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate17$131,861
Invega SustennaPaliperidone Palmitate35$85,850
Abilify MaintenaAripiprazole18$45,862
Lurasidone Hcl33$30,140
Risperdal ConstaRisperidone Microspheres35$28,938
RexultiBrexpiprazole13$17,425
Aripiprazole242$14,709
TrintellixVortioxetine Hydrobromide12$5,385
Chlorpromazine Hcl23$5,037
Paliperidone ErPaliperidone26$4,129
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl27$4,090
Quetiapine Fumarate302$3,588
Fluphenazine Hcl34$3,453
Haloperidol Decanoate65$3,399
Bupropion XlBupropion Hcl271$3,228

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$17$5,38512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,119 psychiatry providers in New Jersey.

Other psychiatry in New Brunswick

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →